ARM makes little difference to cataract surgery outcomes

Article

Patients with age-related maculopathy (ARM) undergoing cataract surgery can expect favourable visual and quality of life outcomes one to three years following surgery, according to the results of a study published in the March issue of Eye.

Patients with age-related maculopathy (ARM) undergoing cataract surgery can expect favourable visual and quality of life outcomes one to three years following surgery, according to the results of a study published in the March issue of Eye.

Jie Jin Wang and colleagues from the University of Sydney and the Westmead Hospital, New South Wales, Australia re-examined patients with and without ARM who had undergone cataract surgery between 2001 and 2003. They tested visual acuity (VA) and assessed visual and health-related quality of life (HRQoL) using standardized questionnaires (VF-14, SF-12). Preoperative co-morbidity data was collected from medical records. Poor surgical outcomes (VA< 6/12; no improvement in VA; lowest quintile of VF-14, SF-12 scores) were compared in subjects with and without ARM.

A total of 454 patients were followed up for a mean period of 2.8 years. Similar numbers of patients in the ARM and non-ARM groups had VA< 6/12, equating to 80.2% and 88.8%, respectively. Preoperative early ARM was associated with a slightly lower mean VF-14 score. Increasing age and preoperative ocular co-morbidities were associated with all poor outcomes measured.

The results of this study suggest that patients with ARM who have undergone cataract surgery can expect reasonable outcomes over three years.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.